Pomotrelvir (PBI-0451) is a selective, orally active SARS-CoV-2 3CL protease inhibitor. Pomotrelvir has antiviral activity and can be used in the research of novel coronavirus (COVID-19).
References:
[1]. Jessica R.Spengler, et al. Meeting report: 35th International Conference on Antiviral Research in Seattle, Washington, USA – March 21–25, 2022.
















